Tandem Diabetes Care (TNDM) Expected to Announce Quarterly Earnings on Wednesday

Tandem Diabetes Care (NASDAQ:TNDM) will likely be announcing its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $251.39 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Tandem Diabetes Care Stock Performance

NASDAQ:TNDM opened at $32.62 on Wednesday. The company has a market cap of $2.14 billion, a P/E ratio of -16.90 and a beta of 1.32. The firm’s 50 day moving average is $35.63 and its two-hundred day moving average is $36.95. Tandem Diabetes Care has a fifty-two week low of $22.03 and a fifty-two week high of $53.69. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TNDM shares. Citigroup cut their target price on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Morgan Stanley raised Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price objective on the stock in a research note on Monday, December 2nd. Canaccord Genuity Group dropped their target price on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Sanford C. Bernstein started coverage on shares of Tandem Diabetes Care in a research report on Wednesday, November 6th. They set an “outperform” rating and a $42.00 price target on the stock. Finally, Robert W. Baird dropped their price objective on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research report on Thursday, November 7th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, Tandem Diabetes Care has a consensus rating of “Moderate Buy” and an average target price of $53.81.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.